+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Continuous Bioprocessing Market by Product (Bioreactors, Cell Culture Media & Reagent, Centrifuges), Process (Downstream Bioprocess, Upstream Bioprocess), Application, Scale of Operation, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 195 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5012940
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Continuous Bioprocessing Market grew from USD 233.44 million in 2023 to USD 282.42 million in 2024. It is expected to continue growing at a CAGR of 21.30%, reaching USD 902.23 million by 2030.

Continuous bioprocessing allows for the uninterrupted flow of materials and products through the production cycle, offering potential improvements in efficiency, quality control, and scalability, unlike traditional batch processing, which processes a fixed volume of products in discrete steps. Pharmaceutical industries are advancing, and government support for the sector is the principal driver of growth for continuous bioprocessing. Increased benefits of over-batch processing & uptake of single-use technology and the continued demand for the production of biopharmaceutical products are spurring the adoption of continuous bioprocessing technologies. In contrast, high equipment costs, operational difficulties, and process change concerns pose a challenge to adopting a continuous bioprocess. In addition, regulatory considerations must be managed, as continuous bioprocessing may necessitate new validation strategies to comply with the stringent standards set by health authorities. However, several market vendors invest in research and development to address many operational challenges in the continuous bioprocessing technologies and further chart to expand the market. Moreover, the adoption of perfusion is associated with single-use equipment, and the development of a continuous bioprocessing approach to stromal cell manufacturing is expected to enhance overall market growth in the coming years significantly.

Regional Insights

In the American region, the adoption of continuous bioprocessing is driven by a strong focus on innovation in biomanufacturing, significant investments in the biotech sector, and a regulatory environment encouraging advanced production techniques. With major pharmaceutical companies and biotech startups striving to achieve more efficient, cost-effective, and scalable manufacturing processes, continuous bioprocessing offers a competitive advantage. Additionally, the presence of a robust technological infrastructure and highly skilled workforce has facilitated the transition from traditional batch processes to continuous approaches in the Americas. Furthermore, in EMEA, high operational costs and stringent regulatory standards have pushed companies to adopt continuous bioprocessing to reduce costs and enhance the quality of biologics. The European pharmaceutical landscape is known for its strong emphasis on innovation and sustainability, which is further reflected in its rapidly growing biosimilar market, where continuous bioprocessing delivers substantial benefits in terms of production agility and speed to market. Additionally, adopting such processes is nascent in the Middle East and Africa. In this region, the continuous bioprocessing is expected to grow by the increasing need for biologics and efforts to localize pharmaceutical production capabilities. The APAC region has seen a surge in adopting continuous bioprocessing due to its rapidly expanding biopharmaceutical sector and the need to compete globally. A growing patient population needs high-quality biologics, increasing investments from players in biotechnology, and supportive government initiatives aiming to boost biomanufacturing capabilities. Several countries have demonstrated significant interest in incorporating continuous processes to accelerate drug development and production timelines, reduce manufacturing footprints, and enable cost savings, all while complying with international quality standards.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Continuous Bioprocessing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Growing demand for biopharmaceuticals & government support for the industry
  • Increased benefits over batch processing & uptake of single-use technology
  • Advent of industry 4.0 & trend towards automation & digitization

Market Restraints

  • Strict regulations for continuous bioprocessing coupled with high equipment cost

Market Opportunities

  • Adoption of perfusion associated with single-use equipment
  • Development of a continuous bioprocessing approach to stromal cell manufacturing

Market Challenges

  • Issues with operational difficulties and process changes

Market Segmentation Analysis

  • Product: Growing preference for bioreactors in large-scale production of recombinant proteins
  • Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity
  • Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health
  • Scale of Operation: Growing application of continuous bioprocessing in the clinical operations
  • End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Continuous Bioprocessing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Continuous Bioprocessing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale

WuXi Biologics announced that it has accomplished end-to-end DS manufacturing at a pilot scale utilizing WuXiUPTM, a proprietary ultra-high productivity continuous bioprocessing platform. This well-configured bioprocess is being scaled up to GMP manufacturing and is going to be deployed across WuXi Biologics' global manufacturing sites in China, Ireland, the U.S., and Singapore.

Sartorius and Repligen Launch Integrated Bioreactor System

Sartorius and Repligen launched an integrated bioreactor system incorporating Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor. According to both companies, the goal is to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.

3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology

3M company announced an investment of USD 146 million to expand its capabilities to support biotech manufacturing. This investment is going to accelerate 3M's development and delivery of vital filtration equipment developed for biological, bioprocessing, and small molecule pharmaceutical manufacturing applications, which enable biotech customers to continue to innovate therapies used for the treatment of conditions including multiple sclerosis, rheumatoid arthritis, and certain cancers.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Continuous Bioprocessing Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Continuous Bioprocessing Market, highlighting leading vendors and their innovative profiles. These include 3D Biotek LLC, 3M Company, Adolf Kühner AG, bbi-biotech GmbH, Belach Bioteknik AB, Bio-Rad Laboratories, Inc., Bionet Servicios Técnicos S.L., Colder Products Company, Danaher Corporation, Esco Aster Pte Ltd., Esco VacciXcell, FiberCell Systems Inc., Fujifilm Holdings Corporation, GE HealthCare Technologies Inc., GEA Group, Getinge AB, Infors AG, Merck KGaA, Repligen Corporation, Sartorius AG, simAbs NV, Suzhou Transcenta Therapeutics Co., Ltd., Thermo Fisher Scientific Inc., Watson-Marlow Fluid Technology Group, and WuXi Biologics Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Continuous Bioprocessing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Product

  • Bioreactors
  • Cell Culture Media & Reagent
  • Centrifuges
  • Chromatography System
  • Filtration Systems
  • Incubators & Shakers

Process

  • Downstream Bioprocess
  • Upstream Bioprocess

Application

  • Cell & Gene Therapy
  • Monoclonal Antibodies
  • Vaccines

Scale of Operation

  • Clinical Operations
  • Commercial Operations

End-User

  • Academic & Research Institutes
  • Contract Development & Manufacturing Organizations
  • Pharmaceutical & Biotechnology Companies

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

Additional Product Information:

  • The purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
  • With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase
  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for biopharmaceuticals & government support for the industry
5.1.1.2. Increased benefits over batch processing & uptake of single-use technology
5.1.1.3. Advent of industry 4.0 & trend towards automation & digitization
5.1.2. Restraints
5.1.2.1. Strict regulations for continuous bioprocessing coupled with high equipment cost
5.1.3. Opportunities
5.1.3.1. Adoption of perfusion associated with single-use equipment
5.1.3.2. Development of a continuous bioprocessing approach to stromal cell manufacturing
5.1.4. Challenges
5.1.4.1. Issues with operational difficulties and process changes
5.2. Market Segmentation Analysis
5.2.1. Product: Growing preference for bioreactors in large-scale production of recombinant proteins
5.2.2. Process: Rising usage of upstream processes owing to progress in terms of efficiency and capacity
5.2.3. Application: Extensive utilization of continuous bioprocessing in the vaccine industry to improve public health
5.2.4. Scale of Operation: Growing application of continuous bioprocessing in the clinical operations
5.2.5. End-User: Significant role of continuous bioprocessing in CDMO as they prioritize flexibility and service offering enhancements for their clients
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Continuous Bioprocessing Market, by Product
6.1. Introduction
6.2. Bioreactors
6.3. Cell Culture Media & Reagent
6.4. Centrifuges
6.5. Chromatography System
6.6. Filtration Systems
6.7. Incubators & Shakers
7. Continuous Bioprocessing Market, by Process
7.1. Introduction
7.2. Downstream Bioprocess
7.3. Upstream Bioprocess
8. Continuous Bioprocessing Market, by Application
8.1. Introduction
8.2. Cell & Gene Therapy
8.3. Monoclonal Antibodies
8.4. Vaccines
9. Continuous Bioprocessing Market, by Scale of Operation
9.1. Introduction
9.2. Clinical Operations
9.3. Commercial Operations
10. Continuous Bioprocessing Market, by End-User
10.1. Introduction
10.2. Academic & Research Institutes
10.3. Contract Development & Manufacturing Organizations
10.4. Pharmaceutical & Biotechnology Companies
11. Americas Continuous Bioprocessing Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Continuous Bioprocessing Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Continuous Bioprocessing Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
14.3.2. Sartorius and Repligen Launch Integrated Bioreactor System
14.3.3. 3M To Invest Nearly USD 150 Million To Advance Capabilities In Biopharma Filtration Technology
14.4. Strategy Analysis & Recommendation
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
List of Figures
FIGURE 1. CONTINUOUS BIOPROCESSING MARKET RESEARCH PROCESS
FIGURE 2. CONTINUOUS BIOPROCESSING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CONTINUOUS BIOPROCESSING MARKET DYNAMICS
FIGURE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2030 (%)
FIGURE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. CONTINUOUS BIOPROCESSING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. CONTINUOUS BIOPROCESSING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CONTINUOUS BIOPROCESSING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY BIOREACTORS, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL CULTURE MEDIA & REAGENT, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CENTRIFUGES, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CHROMATOGRAPHY SYSTEM, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY FILTRATION SYSTEMS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY INCUBATORS & SHAKERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY DOWNSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY UPSTREAM BIOPROCESS, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CLINICAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY COMMERCIAL OPERATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 50. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 51. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 52. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 53. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 54. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 55. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 56. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 57. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 58. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 59. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 60. AMERICAS CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 61. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 62. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 63. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 64. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 65. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 66. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 67. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 68. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 69. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 70. ARGENTINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 71. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 72. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 73. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 74. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 75. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 76. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 77. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 78. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 79. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 80. BRAZIL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 81. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 82. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 83. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 84. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 85. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 86. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 87. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 88. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 89. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 90. CANADA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 91. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 92. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 93. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 94. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 95. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 96. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 97. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 98. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 99. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 100. MEXICO CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 101. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 102. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 103. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 104. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 105. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 106. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 107. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 108. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 109. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 110. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 111. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 112. UNITED STATES CONTINUOUS BIOPROCESSING MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 113. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 114. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 115. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 116. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 117. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 118. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 119. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 120. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 122. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 124. ASIA-PACIFIC CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 125. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 126. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 127. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 128. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 129. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 130. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 131. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 132. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 133. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 134. AUSTRALIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 135. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 136. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 137. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 138. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 139. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 140. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 141. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 142. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 143. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 144. CHINA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 145. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 146. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 147. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 148. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 149. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 150. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 151. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 152. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 153. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 154. INDIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 155. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 156. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 157. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 158. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 159. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 160. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 161. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 162. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 163. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 164. INDONESIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 165. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 166. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 167. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 168. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 169. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 170. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 171. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 172. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 173. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 174. JAPAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 175. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 176. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 177. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 178. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 179. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 180. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 181. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 182. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 183. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 184. MALAYSIA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 185. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 186. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 187. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 188. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 189. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 190. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 191. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 192. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 193. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 194. PHILIPPINES CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 195. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 196. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 197. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 198. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 199. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 200. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 201. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 202. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 203. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 204. SINGAPORE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 205. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 206. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 207. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 208. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 209. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 210. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 211. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 212. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 213. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 214. SOUTH KOREA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 215. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 216. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 217. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 218. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 219. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 220. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 221. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 222. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 223. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 224. TAIWAN CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 225. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 226. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 227. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 228. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 229. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 230. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 231. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 232. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 233. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 234. THAILAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 235. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 236. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 237. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 238. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 239. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 240. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 241. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 242. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 243. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 244. VIETNAM CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 249. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 250. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA CONTINUOUS BIOPROCESSING MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 257. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 258. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 259. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 260. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 261. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 262. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 263. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 264. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 265. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 266. DENMARK CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 267. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 268. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 269. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 270. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 271. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 272. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 273. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 274. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 275. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 276. EGYPT CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 277. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 278. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 279. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 280. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 281. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 282. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 283. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 284. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 285. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 286. FINLAND CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 287. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 288. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 289. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 290. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 291. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 292. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 293. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 294. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 295. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 296. FRANCE CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 297. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 298. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 299. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 300. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 301. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 302. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 303. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 304. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 305. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 306. GERMANY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 307. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 308. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 309. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 310. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 311. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 312. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 313. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 314. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 315. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 316. ISRAEL CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 317. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 318. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 319. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 320. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 321. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 322. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
TABLE 323. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2018-2023 (USD MILLION)
TABLE 324. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY SCALE OF OPERATION, 2024-2030 (USD MILLION)
TABLE 325. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 326. ITALY CONTINUOUS BIOPROCESSING MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 327. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
TABLE 328. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
TABLE 329. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2018-2023 (USD MILLION)
TABLE 330. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY PROCESS, 2024-2030 (USD MILLION)
TABLE 331. NETHERLANDS CONTINUOUS BIOPROCESSING MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
TABLE 332. NETHERLANDS CONTINUOUS BIOPROCESSING MA

Companies Mentioned

  • 3D Biotek LLC
  • 3M Company
  • Adolf Kühner AG
  • bbi-biotech GmbH
  • Belach Bioteknik AB
  • Bio-Rad Laboratories, Inc.
  • Bionet Servicios Técnicos S.L.
  • Colder Products Company
  • Danaher Corporation
  • Esco Aster Pte Ltd.
  • Esco VacciXcell
  • FiberCell Systems Inc.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies Inc.
  • GEA Group
  • Getinge AB
  • Infors AG
  • Merck KGaA
  • Repligen Corporation
  • Sartorius AG
  • simAbs NV
  • Suzhou Transcenta Therapeutics Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Watson-Marlow Fluid Technology Group
  • WuXi Biologics Co., Ltd.

Methodology

Loading
LOADING...

Table Information